TransCode Therapeutics (RNAZ) said Sunday it has agreed to sell about 10.3 million shares of its common stock and warrants to purchase up to 10.3 million shares at a price of $0.98 per share and accompanying warrant for total expected gross proceeds of $10 million.
The warrants will be exercisable at a price of $0.86 per share.
Net proceeds will be used for product development activities, working capital and other general corporate purposes, the company said.
Closing of the offering is expected to occur Tuesday, subject to customary closing conditions.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。